7. Cross-Cutting Observations, Oddities and Divergences

These are patterns that only become visible when the acute, bridge, preventive, neuromodulation and access material are read side by side. Individual items are also flagged within their own sections; they are gathered here because several of them recur across every treatment category and are easy to miss if the chapter is read section-by-section rather than as a whole.

7.1 The episodic/chronic split is the dominant axis of this entire chapter

peer-reviewed citizen science Wherever a treatment’s trial or survey data is broken down by CH subtype, chronic patients do worse — sometimes dramatically so. Zolmitriptan 10 mg intranasal: 80% response episodic vs 36% chronic (Cittadini 2006). GON block complete response 67.2% vs 50%, pain-free duration 33.6 vs 14.3 days (Gaul 2017); Merli complete response 47.8% vs 33.3% (Merli 2022). A survey meta-analysis found oxygen and triptans both significantly less effective in chronic CH (Rusanen 2022). Verapamil: 94% vs 55% complete relief in one comparison (Blau & Engel), 44% vs 34% real-world response in a Danish survey. Melatonin: 50% responders episodic vs 0/2 chronic. Topiramate: 26% vs 10%. Galcanezumab: positive episodic trial, negative chronic trial. Eptinezumab: failed even in episodic. Almost every drug and procedure in this chapter works less well, more slowly, or not at all in chronic disease than the headline figure you will most often be quoted implies — and the headline figure is almost always the episodic one. Lithium is the notable partial exception: it has the strongest open-label data specifically in chronic CH, and is also the one major preventive whose use in chronic CH has never been put through a randomised trial (Section 3.2).

7.2 The citizen-science ranking largely validates clinical evidence — with one major exception

citizen science Rusanen et al.’s hierarchical clustering of 8 patient surveys (5,419 respondents combined) places corticosteroids and verapamil in the high-efficacy prophylactic clade, and melatonin, valproic acid, gabapentin, amitriptyline and propranolol in the low-efficacy clade — concluding the “reported order of efficacy is generally in agreement with clinical studies” with “no results disagreeing with the current knowledge” (PMC9436841). The exception: serotonergic psychedelics (LSD, psilocybin, ergoline alkaloids such as LSA) rank highest of all self-reported prophylactics, at roughly 75% efficacy — above verapamil and above corticosteroids — despite essentially no randomised evidence at the time of that review. This sits outside the scope of a chapter organised around conventional pharmacology and procedures, but it is the single largest gap between community-reported efficacy and formal trial evidence identified anywhere in this research pass, and is flagged here so it is not lost. The reviewers themselves caution that support-group samples may be systematically less satisfied with conventional treatment (deflating verapamil/steroid rankings) and that some patient communities openly endorse tryptamines and ergolines (inflating that ranking) — both biases point the same direction, so the true effect size is more uncertain than the survey ranking alone suggests, but the pattern itself is unlikely to be pure artefact.

7.3 Cardiac monitoring failure on verapamil is real and documented from two independent directions, and the danger window is wider than commonly advised

peer-reviewed community report 41% of 217 patients on a mean 512 mg/day of verapamil had never had an ECG in one peer-reviewed case series (Section 3.1); r/clusterheads users independently and repeatedly report never being offered ECG monitoring despite reporting cardiac symptoms. This matters because arrhythmia risk is not confined to the titration period — in a French series roughly 75% of serious arrhythmias appeared more than two years into treatment and were not clearly dose-dependent (Section 3.1). The common patient-facing advice to relax monitoring once a stable dose is reached is not well supported by that data.

7.4 Access, not efficacy, is frequently the binding constraint — and this cuts across every treatment category, not just oxygen

peer-reviewed community report Oxygen has one of the best benefit-to-harm ratios of any CH treatment and no meaningful daily-use ceiling, and it is simultaneously the treatment patients are most likely to be unable to obtain through their health system. US Medicare patients report paying over $5,000/year out of pocket (Section 5.2); UK smokers and their housemates can be excluded from home oxygen supply outright under some local policies (Section 5.3); Australians have no PBS pathway for oxygen at all and pay privately (Section 5.1); Germany and Japan, by contrast, have oxygen specifically licensed and reimbursed for CH (Section 5.4). The same pattern repeats for CGRP mAbs (PBS-listed for migraine but not cluster headache in Australia; EMA-rejected in Europe) and for gammaCore (TGA-registered in Australia but with no subsidy attached). In this disease, whether a treatment reaches a patient is often decided by which country’s reimbursement paperwork they are filed under, independent of how good the evidence for that treatment actually is.

7.5 Language bias in the literature is measurable, not hypothetical, and non-English sourcing changed several conclusions in this chapter

peer-reviewed Some systematic reviews explicitly exclude non-English sources (one review excluded 19 non-English articles outright; another searched English-language terms only). Material that surfaced only in non-English sources during this research and materially affected specific sections: Japan’s 7 L/min oxygen flow guideline and 2018 home-oxygen reimbursement criteria (Section 1.1 / 5.5); Germany’s 2007 BfArM licensing of oxygen specifically for cluster headache, including a model prescription with cylinder sizing (Section 5.4); Danish real-world survey data on verapamil response rates that conflict with the pivotal RCT (Section 3.1); and German clinic dosing protocols for verapamil that contradict the dominant English-language community view on immediate-release vs sustained-release formulation (Section 3.1). Roughly a third of the practically useful detail in this chapter’s preventive and access sections came from non-Anglophone sources, and the chapter is very likely still missing relevant Scandinavian, Italian, Japanese and Chinese clinical literature that a fully multilingual search would surface.

7.6 Community practice on hardware/technique frequently outruns formal guidance; community explanations of mechanism frequently lag behind or diverge from it

community report peer-reviewed The community’s insistence on non-rebreather masks, reservoir bags, blocking side vents, high flow rates and demand valves for oxygen delivery is grounded in real gas-delivery physics and is supported by FiO₂ measurement data. Its explanatory folk-physiology account of hypothalamic “false alarms” and dilating blood vessels is not established mechanism. Similarly, community reports of hair loss on galcanezumab (reported independently across at least three separate r/clusterheads threads) and of tachyphylaxis developing 6–24 months into CGRP mAb treatment (Section 3.6) are not captured in any labelled adverse-event list or published trial — not because they are false, but because nobody has formally studied either. Take the accumulated technique seriously; treat the folk mechanism and the unstudied side-effect reports as flagged-but-unverified, not as established fact.

7.7 The field has been strikingly static for 20–25 years, with a partial exception in neuromodulation

peer-reviewed The pivotal verapamil trial is from 2000. The lithium-vs-verapamil comparison is from 1990. The one positive melatonin trial is from 1996. The capsaicin trial is from 1993. The clonidine pilot is from 1995. The baclofen pilot is from 2001. The warfarin trial (Section 3.5), with the single best NNT in the entire chapter (2.6), is from 2011 and has never been replicated in fifteen years. The one genuinely new pharmacological mechanism of the last decade — CGRP blockade — has now failed to show benefit in chronic CH across one adequately powered RCT and, per the 2026 meta-analyses that agree on this point even while disagreeing on episodic CH, the chronic-CH null result looks robust (Section 3.6). Neuromodulation is the partial exception: SPG stimulation and posterior-hypothalamic DBS are genuinely newer developments with their own trial bases, though the best-evidenced device (SPG stimulation) is no longer commercially available because its manufacturer dissolved (Section 4.2) — itself a striking failure mode, where the evidence problem in a treatment has been solved but the access problem has gotten worse, not better.

7.8 The disease’s severity is independently documented, not a matter of patient self-report alone

peer-reviewed Suicidal ideation is reported in 55% of CH patients in peer-reviewed data (Brandt et al. 2020). Japan’s national headache society guideline states plainly that in severe cases self-harm to the head and suicide attempts have been reported, and describes the pain as characterised as stronger than labour pain. Australian Prescriber notes the colloquial name “suicide headache” and a diagnostic delay of up to eight years. This is documented in mainstream peer-reviewed and guideline literature, independently of the patient-forum record — it is a recognised clinical feature of the disease, not an exaggeration of it.